Zacks Research Comments on Esperion Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research decreased their Q1 2025 earnings per share estimates for Esperion Therapeutics in a note issued to investors on Tuesday, October 8th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.16) for the quarter, down from their prior forecast of ($0.15). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q2 2025 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.25) EPS and FY2026 earnings at ($0.02) EPS.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million.

Other equities analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. Bank of America cut Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $2.90 to $2.50 in a research note on Thursday, June 20th. Needham & Company LLC lowered their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. Finally, StockNews.com upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, October 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Price Performance

ESPR stock opened at $1.89 on Friday. Esperion Therapeutics has a one year low of $0.70 and a one year high of $3.40. The company’s 50 day moving average price is $1.82 and its two-hundred day moving average price is $2.19.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. BOKF NA bought a new stake in shares of Esperion Therapeutics in the second quarter worth about $26,000. Xponance Inc. purchased a new position in shares of Esperion Therapeutics during the second quarter valued at approximately $28,000. CVI Holdings LLC purchased a new stake in Esperion Therapeutics in the first quarter worth $37,000. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the second quarter valued at $44,000. Finally, National Bank of Canada FI increased its position in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares during the period. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.